



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 06 Dec 2021 (#39)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizek@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

- [NOT-AI-22-005](#) Notice of Early Expiration of PAR-19-078, "Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)". The purpose of this Notice is to inform the extramural community of the early expiration of [PAR-19-078](#) - Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed), effective immediately. The Key Dates section of the FOA has been modified to change the Expiration Date from January 8, 2022 to November 29, 2021. Applicants are encouraged to consider applying to [NOT-AI-21-082](#), "Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity".
- [NOT-AI-22-009](#) Notice of Early Expiration of PA-19-077, "Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)". The purpose of this Notice is to inform the extramural community of the early expiration of [PA-19-077](#) - Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed), effective immediately. The Key Dates section of the FOA has been modified to change the Expiration Date from January 8, 2022 to December 2, 2021. Applicants are encouraged to consider applying to [NOT-AI-22-014](#), "Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery".
- [NOT-AR-22-013](#) Notice to Extend [NOT-AR-20-005](#), "Notice of Special Interest: Promoting research opportunities on HIV/AIDS in NIAMS" The purpose of this Notice is to extend the expiration date for applications submitted to the Notice of Special Interest (NOSI) NOT-AR-20-005. Current Expiration Date: January 08, 2022. **Modified Expiration Date: January 10, 2023**

- [NOT-HD-21-050](#) **Notice of NICHD Participation in [NOT-OD-20-055](#), "Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards"**. The purpose of this Notice is to inform potential applicants that the *Eunice Kennedy Shriver* National Institute of Child Health & Human Development (NICHD) is participating, effective immediately, in [NOT-OD-20-055](#) "Notice of Special Interest (NOSI). The overarching goal of this pilot program is to enhance the retention of investigators facing critical life events who are transitioning to the first renewal of their first independent research project grant award or to a second new NIH research project grant award. This retention program seeks to maintain the productivity of current first-time recipients of eligible independent NIH research project grant awards who are dealing with a critical life event(s), such that they can remain competitive for the first renewal of their award or for a second research project grant award. For retention supplements to support the transition from K award to independence, see the companion NOSI. PD/PIs of the following activity codes are eligible for the program: , [R01](#), [R21](#), [R35](#), and [U01](#) and who have a qualifying critical life event. PD/PIs with more than one independent research project grant award are ineligible for this supplement. Supplement requests must be submitted in accordance with the parent program announcement: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) [PA-18-591](#) or its subsequent reissued equivalent. Qualifying Critical Life Events: The PD/PI must demonstrate a critical life event such as childbirth or adoption during the parent grant project period; or primary caregiving responsibilities of an ailing spouse, partner, or a member of the immediate family. In circumstances in which the critical life event is pending and is expected to occur during the project period, the supplement period may be submitted in advance of the event. For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any of the PDs/PIs (in accordance with the existing leadership plan and on behalf of the PD/PI who meets the eligibility criteria) and submitted by the grantee institution of the parent award. It should be noted that for the parent grant and for the administrative supplement, the grantee is the institution, not the PD/PI. **It is strongly recommended that the applicants contact their respective program officers at the Institute supporting the parent award to confirm ahead of time that the supplement falls within scope of the parent award.**

Notices of Special Interest

- [NOT-AI-21-082](#) **Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity**. The purpose of this Notice of Special Interest (NOSI) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. This notice applies to due dates on or after **February 5, 2022**, and subsequent receipt dates through **January 7, 2025**. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs).
 - [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
 - [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

This NOSI will **NOT** support:

- Studies that propose the use of targeted gene sequencing panels, which analyze specific mutations known to cause inborn errors of immunity/primary immunodeficiency diseases, since they will not aid in the identification of novel disease-causing mutations;
 - Characterization of somatic mutations;
 - Phenocopies of inborn errors of immunity/primary immunodeficiency diseases;
 - Applications that focus on HIV/SIV/AIDS.
- [NOT-AI-22-014](#) **Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery**. The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants about an area of special interest to NIAID on early phase translational research that will generate new malaria vaccine candidates with desirable features suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead

to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially *Plasmodium falciparum* and *Plasmodium vivax*. This notice applies to application receipt dates on or after **February 5, 2022** and subsequent receipt dates through **January 7, 2025**. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements:

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

- **[NOT-CA-22-003](#) Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology.** The purpose of this Notice of Special Interest (NOSI) is to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert substantial impact on gene expression and function, there are a lack of mechanistic insights into the dynamic regulation of RNA modifications and how their de-regulation drives cancer formation. A better understanding of the extent, diversity and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underly cancer formation and the cancer phenotype. **Applications that will be considered nonresponsive to this NOSI will include those focused on Clinical trials.** Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)
 - [PA-20-195](#) NIH Exploratory/Development Research Grant Program (Parent R21 Clinical Trial Not Allowed)
 - [PAR-20-052](#) NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)
 - [RFA-CA-22-001](#) Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
 - [RFA-CA-22-002](#) Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

- **[NOT-DA-23-002](#) Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs.** The mission of the Division of Neuroscience and Behavior of NIDA is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. As a component of the Division, the Chemistry and Pharmacology Branch supports research on all aspects of the chemistry and pharmacology of addictive drugs. The Branch develops and oversees a broad portfolio encompassing research on substance use disorders (SUD) and overdose designed to: 1) elucidate mechanisms of action, synthetic and biosynthetic methodologies, structure-activity relationships, pharmacology and toxicity of addictive drugs, and determination of 3D structures of ligands bound to biological targets, 2) develop new receptor type and subtype specific agents, and 3) discover and advance the pre-clinical development of new pharmacotherapies for the treatment of SUD and overdose, emphasizing the pre-clinical stages of target identification through hit-to-lead. This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through May 8, 2025. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)
 - [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
 - [PA-20-195](#) NIH Research Project Grant (Parent R21 Clinical Trial Not Allowed)
 - [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
 - [PAR-21-208](#) Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

Funding Opportunity Announcements (FOA)

1. Drug Discovery for Nervous System Disorders (R01 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-031](#)

Type: R01

Application Due Date: February 05, 2022; June 05, 2022; February 05, 2023 through to October 05, 2024 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

Companion Funding Opportunities: [PAR-22-032](#) , [R21](#) Exploratory/Developmental Grants

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. Scope of the proposed project should determine the project period. The maximum period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

2. Resource Networks for Protein Polymorphisms in Alzheimer's Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-22-030](#)

Type: U24

Application Due Date: January 10, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites U24 Cooperative Agreement applications aiming to establish misfolded protein polymorphisms resource networks in the area of Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). The central goal of these resource networks is to standardize and distribute seed, oligomers, and fibrils to other investigators in order to clarify and improve the reproducibility of experiments in AD/ADRD. Establishing standards, understanding the pathological roles of these protein polymorphs, and using newly developed analytic tools to address the direct correlation between patient-to-patient variations in A β , α -synuclein, and tau polymorphs are the long-term goals of the resource networks supported by this FOA.

Budget: NIA intends to commit \$3 million in fiscal year 2022 to fund 2 awards. Application budgets may not exceed \$1 million in direct costs per year. Budgets must reflect the actual needs of the proposed project. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105